Oct 31 (Reuters) - Equillium Inc :
* EQUILLIUM INC - IT WAS TEMPORARILY PAUSING ENROLLMENT IN ITS EQUATOR STUDY
* EQUILLIUM INC - TEMPORARILY PAUSING ENROLLMENT IN EQUATOR STUDY, PHASE 3 CLINICAL STUDY OF ITOLIZUMAB (EQ001) IN ACUTE GRAFT-VERSUS-HOST DISEASE
* EQUILLIUM INC - REPOSITIONED ITOLIZUMAB (EQ001) AS ITS TOP PRIORITY IN ITS PIPELINE
* EQUILLIUM INC - TAKING OPERATIONAL STEPS TO EXTEND ITS CASH RUNWAY, WHICH MEASURES ARE EXPECTED TO PROVIDE OPERATING RUNWAY INTO Q4 2025
* EQUILLIUM INC - AS PART OF OPERATIONAL STEPS, COMPANY IS PAUSING FURTHER ACTIVITIES RELATED EQ101 AND EQ302
* EQUILLIUM INC - EFFECTIVE OCT 30, OPTION AND ONO AGREEMENT AUTOMATICALLY TERMINATED PURSUANT TO TERMS OF ONO AGREEMENT
* EQUILLIUM INC - MAINTAINS ALL OF ITS COMMERCIAL RIGHTS TO ITOLIZUMAB (EQ001)
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.